GlassScriptPhysician profile
John Paul Malayil
NPI 1851554927
$22,985.18
in general payments reported to CMS, 2019-2025
48 companies · $2,487 in 2025
The $2,487 reported for 2025 was more than what 83% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,477 · 2020: $711 · 2021: $3,036 · 2022: $5,122 · 2023: $2,035 · 2024: $7,117 · 2025: $2,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,940 · Consulting Fee: $2,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,939.76 |
| Consulting Fee | $2,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $5,337.15 | 2023-2025 | Prospera, Biotronik |
| Abbott Laboratories | $4,240.52 | 2020-2025 | Octrode, Proclaim, Eterna |
| Nevro Corp. | $3,970.78 | 2019-2023 | Senza |
| Nalu Medical, INC. | $1,998.92 | 2021-2024 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $1,561.98 | 2019-2020 | |
| Boston Scientific Corporation | $1,088.76 | 2019-2024 | Intracept, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $743.44 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $516.39 | 2019-2025 | Relistor |
| Painteq LLC | $507.28 | 2024 | Painteq |
| Vertos Medical, INC. | $467.20 | 2021-2022 | |
| Spinal Simplicity, LLC | $330.88 | 2025 | Ha Minuteman G3-R |
| Collegium Pharmaceutical, INC. | $281.71 | 2019-2025 | Belbuca, Xtampza |
| Stryker Corporation | $275.64 | 2021-2025 | Multigen 2, Mild Device Kit |
| Amgen INC. | $165.51 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $164.21 | 2019-2024 | Ztlido |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Paul Malayil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.